GlassScriptPhysician profile
Lisai Zhang
NPI 1629501911
$2,215.16
in general payments reported to CMS, 2019-2025
19 companies · $528 in 2025
The $528 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $125 · 2023: $217 · 2024: $1,345 · 2025: $528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,090.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,090.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $270.68 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $229.98 | 2024-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $182.05 | 2024 | Amplatzer Talisman |
| Lilly USA, LLC | $179.79 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $168.72 | 2023-2025 | Ubrelvy, Qulipta |
| Medtronic, INC. | $161.54 | 2024 | Linq II |
| Amgen INC. | $140.33 | 2023-2025 | Evenity, Prolia, Otezla |
| Pfizer INC. | $126.89 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $124.99 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $124.99 | 2024 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $124.99 | 2023 | Farxiga |
| Irhythm Technologies, INC. | $103.46 | 2024 | Zio Xt Patch, Zio Monitor |
| Glaxosmithkline, LLC. | $71.72 | 2024-2025 | Arexvy, Shingrix |
| Smith+Nephew, INC. | $71.15 | 2024 | Or3o Dual Mobility, Real Intelligence |
| Boston Scientific Corporation | $36.53 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $34.16 | 2025 | Veozah |
| Idorsia Pharmaceuticals US INC | $29.86 | 2024 | Quviviq |
| Sumitomo Pharma America, INC. | $17.91 | 2025 | Gemtesa |
| Eisai INC. | $15.42 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisai Zhang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.